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Abstract
Background: The standard definition for protocol adherence is the proportion of all scheduled doses that are
delivered. In clinical research, this definition has several limitations when evaluating protocol adherence in trials that
study interventions requiring continuous titration.
Discussion: Building upon a specific case study, we analyzed a recent trial of a continuously titrated intervention
to assess the impact of different definitions of protocol deviations on the interpretation of protocol adherence.
The OVATION pilot trial was an open-label randomized controlled trial of higher (75–80 mmHg) versus lower
(60–65 mmHg) mean arterial pressure (MAP) targets for vasopressor therapy in shock. In this trial, potential
protocol deviations were defined as MAP values outside the targeted range for >4 consecutive hours during
vasopressor therapy without synchronous and consistent adjustments of vasopressor doses. An adjudication
committee reviewed each potential deviation to determine if it was clinically-justified or not. There are four
reasons for this contextual measurement and reporting of protocol adherence. First, between-arm separation is a
robust measure of adherence to complex protocols. Second, adherence assessed by protocol deviations varies in
function of the definition of deviations and the frequency of measurements. Third, distinguishing clinically-justified vs.
not clinically-justified protocol deviations acknowledges clinically sensible bedside decision-making and offers a clear
terminology before the trial begins. Finally, multiple metrics exist to report protocol deviations, which provides different
information but complementary information on protocol adherence.
Conclusions: In trials of interventions requiring continuous titration, metrics used for defining protocol deviations
have a considerable impact on the interpretation of protocol adherence. Definitions for protocol deviations should be
prespecified and correlated with between-arm separation, if it can be measured.
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Background
In clinical practice, adherence is defined as the extent to
which a person’s behaviour corresponds with the recom-
mendations made by a healthcare provider [1, 2]. In a re-
search setting, non-adherence hinders the feasibility of
clinical trials because patients who do not receive the
intended intervention will not be affected by it [3]. In
addition, non-adherence may bias trial results because
patients who do not adhere to study protocols may have
an inherently different prognosis compared to those who
comply with the protocol [4]. Accordingly, variations in
how protocol adherence is monitored and reported may
bear on the interpretation of clinical trials [5–7].
The standard definition for protocol adherence is the
proportion of all scheduled doses that are received [8].
This approach, however, is not applicable to interven-
tions requiring continuous titration where a total num-
ber of scheduled doses is irrelevant. With interventions
like continuous infusions of vasopressors and insulin, as
well as mechanical ventilation, there exist no finite num-
ber of scheduled doses. In this article, we propose an ap-
proach to measure and report adherence in trials of
continuous interventions titrated by bedside teams. This
approach, informed by a recent pilot trial, acknowledges
clinically-justified deviations and contextualizes protocol
adherence into a pragmatic framework.
Discussion
Case study – The OVATION pilot trial
The OVATION pilot trial was an open-label randomized
controlled trial of higher versus lower mean arterial
pressure (MAP) targets for vasopressor therapy in shock
[9]. The trial interventions were developed with input
from clinicians and, with Research Ethics Board approval
at each of 11 participating academic hospitals from
Canada and the United States, we randomly assigned
critically ill patients with vasodilatory shock to a lower
(60–65 mmHg) versus higher (75–80 mmHg) MAP tar-
get. The primary feasibility objective of the trial was to
achieve a 5 mmHg difference in MAP during vasopres-
sor therapy between study groups. Intensive care unit
(ICU) research personnel screened and enrolled eligible
patients and recorded MAP and vasopressor doses
hourly for the duration of vasopressor therapy. This ap-
proach enabled the investigators to measure the time
within, above, and below assigned target MAP ranges,
and to identify whether adjustments to vasopressor infu-
sions complied with the study protocol. From May 2013
to April 2014, 118 patients participated in the OVATION
pilot trial and 117 received vasopressor infusions for 695
patient-days.
In this trial, we defined potential protocol deviations a
priori as MAP values outside the targeted range for >4
consecutive hours during vasopressor therapy without
synchronous and consistent adjustments of vasopressor
doses. As such, out of range MAPs did not constitute
protocol deviations when the bedside team titrated vaso-
pressors as required (i.e., increased dose if MAP was
below the prescribed range or decreased dose if MAP
was too high during the 4-h window). This 4-h time
window was proposed by the steering committee and
approved by all OVATION trial investigators. More-
over, we adjudicated each potential protocol deviation
to determine if these events were clinically justified
(Additional file 1). This approach was in sharp contrast
to the mere reporting of MAP values at selected time
points. Herein, we discuss four advantages of this con-
textual measurement and reporting of protocol adherence
in clinical trials of interventions that require continuous
titration.
Reason 1: Between-arm separation is a robust measure
of adherence to complex protocols.
While protocol deviations may occur with simple
interventions, they are more likely to occur in complex
interventions. Thus, interventions requiring frequent or
continuous titration present the greatest challenge, since
protocol deviations may occur at any moment of the
trial, in contrast to once or at most several times per
day for most other interventions. When designing the
OVATION pilot trial, it was not possible to specify an
acceptable number of ‘missed doses’ for continuous
vasopressor infusions. Instead, the extent of separation
in MAP between arms was chosen as a crucial feasibility
criterion to proceed to a larger trial. Accordingly, we pre-
specified what we considered the minimally acceptable
separation based on clinical considerations, recognizing
that even smaller differences (e.g. difference in MAP
<5 mmHg) may be statistically significant but clinically
unimportant. We observed a mean difference of 9 mmHg
(95% confidence interval: 7 to 11 mmHg; p < 0.01) in
average MAP between arms on days with vasopressors ad-
ministered, thus exceeding the predefined threshold for
feasibility of 5 mmHg.
Reason 2: Adherence assessed by protocol deviations
varies in function of the definition of deviations and the
frequency of measurements.
The ‘80% rule’ refers to the proportion of all scheduled
doses that are received and is often cited as the cutoff
for acceptable adherence for pharmacological interven-
tions [10]. As mentioned above, with continuous inter-
ventions the number of scheduled doses is not finite. As
the frequency of monitoring increases, so do the re-
sources required to track protocol adherence. Close
monitoring of protocol deviations is unlikely in trials
that lack resources, introducing a risk of ascertainment
bias. In contrast, with very frequent monitoring of con-
tinuous interventions, the likelihood of recording proto-
col deviations increases but the clinical impact of each
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deviation diminishes proportionately. Similarly, criteria
for protocol deviations that are too sensitive would exag-
gerate the impact of protocol deviations beyond what is
clinically important and unduly undermine the apparent
feasibility and internal validity of the trial.
In the OVATION pilot trial, we considered reporting
non-adherence as the proportion of hourly MAP values
that were out-of-range during vasopressor therapy
(Table 1a). This approach was dismissed on the basis
that brief fluctuations in MAP values, randomly dis-
tributed above and below the targeted range, would
not capture meaningful protocol deviations. Instead,
we defined potential deviations as MAP values con-
tinuously above or below the targeted range for four
consecutive hours (Table 1b). Furthermore, acknow-
ledging that clinicians might adhere to the protocol
but the patients fail to respond to the intervention, ad-
justments to vasopressor infusions were incorporated
into the definition for protocol deviations. We consid-
ered that blood pressure alone was a poor marker of
protocol adherence and that compliance with medica-
tion delivery was equally important.
Reason 3: Distinguishing clinically-justified vs. not
clinically-justified protocol deviations acknowledges clin-
ically sensible bedside decision-making and offers a clear
terminology before the trial begins.
The existing literature on protocol adherence focuses
mostly on outpatient interventions [2, 11]. In this con-
text, efforts to maximize adherence is directed at study
participants. In other settings, such as critical care,
protocol deviations do not reflect the behavior of study
participants but of the bedside team. During the OVA-
TION pilot trial, a protocol adherence adjudication com-
mittee reviewed 164 database-generated protocol
adherence alerts, representing 94 unique events. Figure
1 and Table 1c illustrate the classification of protocol ad-
herence alerts. After adjudication, 75 of 94 unique
protocol deviation alerts (80%) resulted from situations
where the research team could ascertain no justifiable
reason for the alert (i.e. these protocol deviations were
Table 1 Protocol adherence according to different definitions
Higher MAP Lower MAP p value
(75–80 mmHg) (60–65 mmHg)
N = 58 N = 59a
a. Proportion of total hours on vasopressors in and out of rangeb
Each patient weighted equally
Time within range 33% (30–37%) 28% (24–32%) 0.053
Time above-target 39% (34–45%) 66% (61–71%) <0.001
Time below-target 28% (22–33%) 6% (4–9%) <0.001
Patients weighted proportionally to total hours on VP
Time within range 32% (29–35%) 31% (28–34%) 0.81
Time above-target 34% (30–38%) 61% (56–65%) <0.001
Time below-target 34% (30–39%) 8% (3–13%) <0.001
b. MAP out of range for four consecutive vasopressor hours
Number of occurrences of four consecutive hours/vasopressor days
(mean events per day)
821/378 (2.2) 681/314 (2.2) No important differences
Number of days with MAP out of range for at least four consecutive hours (%) 299/378 (79%) 259/314 (82%) 0.29
Number of patients with at least one occurrence of MAP out of range for four
consecutive hours (%)
56/58 (97%) 57/59 (97%) 1.00
c. MAP values outside the targeted range for four consecutive hours without
synchronous and consistent adjustments of vasopressor doses
Number of deviation events (mean events per day) 32 (0.08) 43 (0.14) 0.03c
Number of days with at least one deviation event (%) 31 (8%) 40 (13%) 0.03d
Number of patients with at least one deviation event (%) 26 (45%) 20 (34%) 0.26e
MAP Mean arterial pressure
aThis excludes 1 patient who did not have a vasopressor infusion
bThe proportion of total hours on vasopressor and within, above or below target were calculated by first determining the proportion of hours on vasopressors
that were within, above or below target for each patient. The patient level data was then used to calculate the target group means, confidence intervals and p-
values comparing the higher and lower MAP target groups. The group level summary statistics were first calculated weighting each patient equally regardless of
hours on vasopressors and were then re-calculated after weighting each patient proportionally to the number of hours they were on vasopressors
cP-value calculated by generalized estimating equations (GEE) with exchangeable within subject working correlation, Poison dependent distribution and log-link
dP-value calculated by GEE with exchangeable within subject working correlation, Poison distribution, log-link and the log of the number of vasopressors days as offset
eP-value calculated Fisher’s exact test
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adjudicated as not clinically-justified). In contrast, 19
protocol adherence alerts corresponded to scenarios
where overruling the protocol was “admissible” as per
predefined criteria (i.e., clinically-justified protocol devi-
ation). When an unforeseen clinical situation justified
the interruption of the trial intervention, we amended
the protocol and did not report the event as a protocol
deviation, judging these situations to be concordant with
usual care [12]. For example, one patient developed
acute aortic regurgitation after randomization. This un-
expected event required a vasopressor dose reduction
and a protocol amendment was prepared for the planned
larger trial mandating that clinicians stop the assigned
intervention in a similar clinical situation. Such careful
assessment of protocol adherence in a pilot study can be
used to characterize usual care and provide other useful
insights into the acceptability of the intervention. During
the OVATION pilot trial, protocol deviations more com-
monly consisted of MAP values above study targets,
even in the higher MAP arm. This was in sharp contrast
with stated practices [13]. Thus, by adjudicating protocol
deviations, we observed that ICU physicians and nurses
appear to be more concerned by the potential risks of
hypotension than by the potential risks of vasopressor
doses required to achieve higher targets. A contextual
analysis of protocol adherence raised the possibility that
aggressive vasopressor use has become embedded in
standard clinical practice.
Reason 4: Multiple metrics exist to report protocol
deviations.
The traditional approach captures the proportion of
patients who receive an arbitrary number of scheduled
doses. A thoughtful approach is needed to understand
the range of reporting options available and to select a
metric for reporting protocol deviations that align with
the trial objectives. In addition to the criteria that define
protocol deviations, the units of measurement also
influence the measure of adherence. Choosing to report
the number of protocol deviation events, the number of
days with at least one deviation event or the number of
patients who ever experienced one protocol deviation
provides different information. In the OVATION pilot
trial, adherence was similar in both arms using the last
definition, but was superior in the high MAP arm when
we used the first two definitions (Table 1).
Building on previous work
Various terminologies describe the numerous issues re-
lated to protocol adherence. Ellis et al. have categorized
non-adherence as ‘erratic adherence’, ‘unwitting non-
adherence’ and ‘intelligent non-adherence’ [10]. In some
trials, the cessation of a trial intervention prompted by
such an event could be considered as a clinically sensible
decision with no further comment, a protocol deviation,
a protocol violation, or even a serious adverse event
without explicit reference to protocol adherence. The
distinction between clinically-justified deviations that are
not avoidable from the trial perspective and those that are
not clinically-justified can be useful to researchers and in-
formed readers of the medical literature [14]. Central and,
Fig. 1 Classification of protocol adherence alerts
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ideally, blinded adjudication of clinical events and associ-
ated protocol decisions can help make these distinctions.
Strengths and limitations
The strengths of this analysis include a priori definitions
for protocol deviations, pilot trial feasibility criteria
based on between-arm separation in MAP and total
vasopressor dose, as well as parallel comparisons be-
tween various metrics. One limitation is that our obser-
vations are nested in a single, small clinical trial
comparing complex critical care interventions and, thus,
do not apply to all settings. Our intention was not to ad-
dress every methodological issue that relates to protocol
adherence. Rather, we used the OVATION pilot trial as
a case study to illustrate that failure to contextualize the
monitoring, reporting and interpretation of protocol ad-
herence may lead to inappropriate conclusions. Another
potential limitation is that there is no objective gold
standard to determine the suitability of alternative ap-
proaches to the monitoring and reporting of protocol
adherence. Admittedly, the definitions of protocol devia-
tions in the OVATION pilot trial were arbitrary (e.g. 4-h
time window). However, this is in keeping with every
other measure of acceptable adherence, such as the 80%
rule, which are typically well accepted. Our intention
was not to present a superior definition for protocol ad-
herence. Rather, the purpose of this analysis was to ex-
emplify how trialists who are mindful of the context in
which a complex research protocols are delivered may
plan the monitoring of protocol adherence. While a
clearer taxonomy of issues related to protocol adherence
would undoubtedly be valuable to trialists and readers of
the medical literature, this project was not designed to
achieve this goal. Finally, our work focused on current
issues related to protocol adherence. In the future, with
the rapid development of real-time, data driven algo-
rithms, the nomenclature for protocol adherence may
yet become even more complex.
Conclusions
Metrics used for defining protocol deviations in a trial
evaluating an intervention requiring continuous titration
can significantly modify the interpretation of protocol ad-
herence. Protocol deviations should be defined a priori and
adapted to the complexity of the clinical context. With
more complex interventions, an adjudication process to
determine whether the deviations encountered were clinic-
ally justified may be warranted.
Additional file
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